Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
national blog main
national top stories
new york top stories
5
×
boston blog main
boston top stories
fda
new york blog main
san francisco top stories
san diego blog main
san diego top stories
san francisco blog main
boston
drugs
national
roche
akcea therapeutics
allergan
allopregnanolone
alnylam pharmaceuticals
andrew fire
billy dunn
biogen
biotech
blueprint medicines
boulder/denver blog main
boulder/denver top stories
brexanolone
bristol-myers squibb
cancer
clinical data
companion diagnostic
craig mello
detroit blog main
detroit top stories
dna sequencing
drug prices
drug pricing
entrectinib
What
approved
5
×
drug
5
×
medicine
5
×
fda
new
oks
specifically
afternoon
alnylam
alnylam’s
atrophy
brexanolone
cancer
daily
data
deeper
depression
devastating
disease
disorder
dna
evrysdi
fast
fatty
fingerprint
friday
genetic
gets
going
green
history
home
horizon
intended
intercept
known
landmark
lights
liquid
liver
Language
unset
Current search:
xconomy.com
×
medicine
×
approved
×
drug
×
" new york top stories "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug